RGEN News and Press, Repligen Corporation From 10/07/19

Shares of Repligen (NASDAQ: RGEN) fell more than 17% last month, according to data provided by S&P Global Market Intelligence . In fact, September was the stock's worst month of 2019, although there wasn't any company-specific news to justify the drop. This simply appears to be a case o...

Shares of Repligen (NASDAQ: RGEN) lost over 13% today, although there doesn't appear to be any company-specific news dragging the stock down. This simply appears to be good old-fashioned volatility caused by the stock's own success. Shares had posted a year-to-date gain of over 75% before to...

NEW YORK , Sept. 6, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following index adjustments to the S&P MidCap 400 and S&P SmallCap 600 to ensure each index more appropriately represents its market capitalization range. The changes will be effective prior to t...

Nine companies are moving into the S&P MidCap 400 index , and 10 joining the SmallCap 600, as part of a September rebalancing. More news on: Selective Insurance Group, Inc., Repligen Corporation, FirstCash, Inc., Stocks on the move Read more ...

The S&P 500  -- along with its predecessor, the S&P Composite -- has only lost value in two 10-year periods dating back to 1926: once around the time of the Great Depression and again in the decade stretching from the peak of the dot-com bubble to the beginning of the Great Recessi...

Repligen (NASDAQ: RGEN ) resumed with Overweight rating and $110 (19% upside) price target at Stephens. More news on: Repligen Corporation, ZIOPHARM Oncology, Inc., Cerus Corporation, Healthcare stocks news, , Read more ...

We run a stock screen that we have named 'The Nosebleed' that filters for the most expensive or richly-priced stocks in the market. The purpose here is to find stocks that are priced so high up in the stands that the air is thin and investors could begin to experience a nasal hemorrhage metaph...

Repligen Corporation (RGEN) Q2 2019 Results Conference Call August 1, 2019 08:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call Participants ...

Repligen (NASDAQ: RGEN ): Q2 Non-GAAP EPS of $0.31; GAAP EPS of $0.17 misses by $0.01 . More news on: Repligen Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...

Reports record quarterly revenue of $70.7 million, representing 48% year-over-year growth and 46% organic growth Raises revenue guidance to $264-$268 million for full year 2019, representing 29%-31% organic growth Completes acquisition of process analytics innovator C Technologies ...